Researchers at the University of Colorado Anschutz Medical Campus studying interactions between nerves and tumor microenvironments have found that commonly used drugs like botox may stop or slow the progression of certain ...
Feb 28, 2024
0
36
A novel treatment for polycythemia vera, a potentially fatal blood cancer, demonstrated the ability to control overproduction of red blood cells, the hallmark of this malignancy and many of its debilitating symptoms in a ...
Feb 21, 2024
0
53
Researchers from the University of Missouri School of Medicine have found potential treatments for two different types of common complications following bone marrow transplantation.
Feb 14, 2024
0
0
Sleep apnea is prevalent among cardio-oncology patients who are at higher risk for congestive heart failure from cancer therapy, according to a new study being presented at the American College of Cardiology Advancing the ...
Feb 9, 2024
0
0
In a new study published in the journal AI in Precision Oncology, Nikhil Thaker, from Capital Health and Bayta Systems, and co-authors, evaluated the performance of various LLMs, including OpenAI's GPT-3.5-turbo, GPT-4, GPT-4-turbo, ...
Feb 8, 2024
0
0
Rates of re-excision after initial breast-conserving surgery in women with breast cancer remain high across the United States, leading to an increased cost of care and a higher risk of postoperative complications, according ...
Feb 6, 2024
0
1
Swiss pharmaceutical giant Novartis said this week it had agreed to buy German biotech firm MorphoSys for 2.7 billion euros ($2.9 billion), giving it access to a new blood cancer treatment.
Feb 6, 2024
0
0
A team of researchers from the Badalona Applied Research Group in Oncology (B·ARGO) and the Urologic Tumors Unit of the Institut Català d'Oncologia (ICO) and the Germans Trias i Pujol Research Institute (IGTP) have found ...
Feb 2, 2024
0
0
Pfizer reported a quarterly loss Tuesday on much lower sales of COVID-19 products as it emphasized progress on cost-cutting and drug development initiatives.
Jan 30, 2024
0
1
Digistain, a company with its roots at Imperial, has proven the worth of its breast cancer assessment method in a significant clinical trial.
Jan 29, 2024
0
0
